Introduction
Irritable bowel syndrome (IBS) affects approximately 4–11% of the global population, depending on the iteration of the Rome diagnostic criteria utilized. [1] Dietary interventions have emerged as first-line management strategies, yet comparative efficacy across different dietary approaches remains unclear. [2] This umbrella review compares the efficacy of dietary interventions for adult IBS patients.
Aims & Methods
Systematic searches were performed across databases through April 2026. Eligible studies included meta-analyses and NMAs of randomized controlled trials (RCTs) evaluating dietary interventions in adults diagnosed with IBS according to Rome criteria. Primary outcomes included failure to achieve global IBS symptom improvement or adequate relief; secondary outcomes comprised quality of life scores, bloating, and abdominal pain. Quality assessment utilized AMSTAR-2 for meta-analyses and GRADE for certainty of evidence. We critically evaluated blinding procedures in primary RCTs, including sham diet designs, patient-reported outcome validity, and nocebo/expectation effects. Heterogeneity and overlap were assessed using corrected covered area (CCA) analysis.
Results
We included 16 meta-analyses encompassing 9,904 patients from 120 unique papers after deduplication. For failure to achieve global IBS symptom improvement, LFD demonstrated superiority over control diets with a relative risk (RR) of 0.51 (95% CI 0.37–0.70) in 24 trials. While LFD ranked fourth overall in NMA effect sizes behind diets with sparse evidence, it was significantly superior to habitual and traditional diets and held the highest evidence certainty. GFD ranked second in effect size (RR 0.45, 95% CI 0.25–0.81) but was evaluated in only one trial, yielding very low evidence certainty. The Mediterranean diet showed the greatest improvement in the IBS Severity Scoring System (IBS-SSS), quality of life, and distension. LFD significantly reduced IBS-SSS (standardized mean difference [SMD] −0.599, p<0.001) and improved quality of life (SMD 0.259, p<0.0001) across five meta-analyses with 3,761 patients. For persistence of abdominal pain, LFD ranked fifth (RR 0.61, 95% CI 0.42–0.89), while for persistence of bloating it ranked fifth (RR 0.55, 95% CI 0.37–0.80). GFD showed only a slight trend for abdominal pain reduction (SMD −0.68, 95% CI −1.36 to 0.00) with no significant effects on overall symptoms or bloating. Critical assessment revealed that no trials achieved a low risk of bias across all domains, though 17 RCTs were low risk except for double-blinding. Only three RCTs were double-blind, with two providing complete meals. Blinding challenges included the inability to mask dietary restrictions, high placebo response rates (38–52%), and potential nocebo effects from food avoidance. Evidence certainty was predominantly low to very low by GRADE criteria, with moderate certainty only for LFD on global symptoms.
Conclusion
Despite ranking lower in absolute NMA effect sizes than under-studied alternatives, the low-FODMAP diet demonstrates the most robust and highest-certainty evidence for improving global IBS symptoms, quality of life, and bloating. The gluten-free diet lacks sufficient evidence for routine recommendation. Future research should prioritize double-blind sham diet designs, objective outcome measures, and standardized Rome IV criteria to strengthen evidence quality and enable personalized dietary management strategies for IBS patients.
References
1. Ballena-Caicedo, J., Valladolid-Sandoval, L. A. M., Zuzunaga-Montoya, F. E., & Vera-Ponce, V. J. (2025). Global Prevalence of Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Gastroenterology research, 18(6), 308–321. https://doi.org/10.14740/gr2095
2. Lewgood, J., Oliveira, B., Korzepa, M., Forbes, S. C., Little, J. P., Breen, L., Bailie, R., & Candow, D. G. (2021). Efficacy of Dietary and Supplementation Interventions for Individuals with Type 2 Diabetes. Nutrients, 13(7), 2378. https://doi.org/10.3390/nu13072378